The global biosimulation market is entering a high-growth phase as pharmaceutical and biotechnology companies increasingly adopt computational approaches to improve drug discovery, development, and clinical decision-making. According to MarketsandMarkets™, the market is projected to grow from approximately USD 4.27 billion in 2026 to USD 9.24 billion by 2031, registering a CAGR of 16.7% during the forecast period.
Browse 300 market data Tables and 50 Figures spread through 400 Pages and in-depth TOC on “Biosimulation Market – Global Forecast to 2031”
Biosimulation Market Size & Forecast
- Market Size Available for Years: 2025–2031
- 2026 Market Size: USD 4.27 billion
- 2031 Projected Market Size: USD 9.24 billion
- CAGR (2026–2031): 16.7%
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=838
Key Biosimulation Market Trends and Insights
The biosimulation market is being shaped by the growing complexity of drug development, increasing adoption of model-informed drug development (MIDD), rapid integration of artificial intelligence into life sciences R&D, and the need to improve R&D productivity while reducing development costs and timelines.
In 2025, the software segment dominated the market by offering, accounting for a 62.8% share. Meanwhile, the early clinical development segment is expected to register the highest CAGR by phase of development during the forecast period. North America dominated the global market with a 48.0% share in 2025, while Asia Pacific is expected to emerge as the fastest-growing regional market.
Biosimulation encompasses a broad range of computational methods, including physiologically based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology (QSP), pharmacometrics, molecular modeling, computational chemistry, and virtual patient simulations. These approaches help researchers select drug candidates, predict drug responses, determine appropriate doses, optimize clinical trial designs, and support regulatory submissions.
Growing Adoption of Biosimulation in Drug Development
The increasing complexity of modern drug discovery and development is one of the major factors accelerating biosimulation adoption. Pharmaceutical companies are working with larger datasets, increasingly complex biological mechanisms, advanced therapeutic modalities, and stricter development requirements.
Biosimulation enables organizations to evaluate drug behavior computationally before conducting extensive laboratory and clinical studies. By generating predictive insights, these tools can support more informed decisions throughout the development lifecycle.
The growing popularity of model-based and model-informed drug development is further expanding opportunities for biosimulation providers. MIDD approaches allow drug developers to integrate modeling and simulation into decision-making related to dose optimization, trial design, patient selection, and regulatory strategy.
At the same time, the integration of artificial intelligence (AI), machine learning, and advanced analytics is creating new opportunities to enhance biosimulation workflows. AI-enabled approaches can help analyze complex biological datasets, improve predictive modeling, and support more efficient drug development strategies.
Services Segment Expected to Grow Faster Than Software
By offering, the services segment is anticipated to register a higher CAGR than the software segment during the forecast period.
Drug development programs increasingly require specialized capabilities in PBPK modeling, QSP, pharmacometrics, pharmacokinetic/pharmacodynamic modeling, regulatory modeling, and data analysis. However, many pharmaceutical and biotechnology companies—particularly small and mid-sized organizations—do not have extensive in-house biosimulation expertise.
As a result, these organizations increasingly rely on specialized third-party providers for model development, validation, data analysis, regulatory support, consulting, and strategic guidance.
The services segment is also benefiting from the increasing incorporation of AI and machine learning into biosimulation. These technologies require specialized scientific, computational, and technical expertise, encouraging companies to seek external support.
The expansion of biologics, cell and gene therapies, and precision medicine is expected to create additional demand for specialized biosimulation services. By outsourcing these activities, drug developers can access specialized expertise while potentially reducing development risks, improving decision-making, and accelerating development timelines.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=838
On-Premises Deployment Maintains Market Leadership
By deployment mode, on-premises solutions accounted for the largest share of the biosimulation market in 2025.
Data security, intellectual property protection, regulatory requirements, and organizational control remain important considerations for pharmaceutical and biotechnology companies. Biosimulation workflows can involve highly sensitive preclinical, clinical, molecular, and proprietary research data, encouraging organizations to maintain computational environments within their internal infrastructure.
Large pharmaceutical companies have also invested substantially in high-performance computing (HPC) infrastructure to support computationally intensive applications such as PBPK modeling, QSP, molecular dynamics, computational chemistry, and AI-enabled drug discovery.
On-premises deployment provides organizations with greater control over data governance, system customization, security, and integration with existing R&D infrastructure. These advantages make on-premises solutions particularly attractive for organizations managing large and complex drug development programs.
Asia Pacific to Register the Fastest Growth
Among the major regional markets—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa—Asia Pacific is projected to be the fastest-growing region during the forecast period.
The region is experiencing increasing investments in pharmaceutical and biotechnology research, expanding drug discovery capabilities, and growing adoption of computational approaches throughout the drug development lifecycle.
Countries including China, India, Japan, South Korea, and Singapore are strengthening their life sciences ecosystems through government-supported research initiatives, expanding biopharmaceutical manufacturing capabilities, and greater adoption of AI and advanced analytics.
The increasing demand for cost-effective approaches to accelerate drug development is also supporting the adoption of biosimulation technologies such as PBPK modeling, QSP, pharmacometrics, and molecular modeling.
Furthermore, the expanding presence of global pharmaceutical companies, contract research organizations (CROs), and academic research institutions is contributing to greater use of biosimulation platforms across Asia Pacific.
Role of Biosimulation in Personalized Medicine and Advanced Therapies
The continued shift toward personalized medicine is expected to create significant opportunities for biosimulation technologies. Traditional drug development approaches often rely on broad patient populations, whereas personalized medicine requires a deeper understanding of patient-specific biological and pharmacological characteristics.
Biosimulation can help researchers evaluate variations in drug response, optimize dosing strategies, and improve patient stratification. This capability is particularly relevant as pharmaceutical companies increasingly develop targeted therapies and complex biologic products.
The growing development of cell and gene therapies is another important opportunity. These therapies often involve complex biological mechanisms and challenging development pathways, creating demand for advanced modeling and simulation approaches that can support research and clinical development decisions.
Regulatory Acceptance Supports Market Expansion
Increasing recognition of modeling and simulation approaches within regulatory decision-making is another factor supporting market development.
Regulatory agencies and pharmaceutical companies are increasingly interested in evidence generated through modeling and simulation to complement experimental and clinical data. As regulatory frameworks and guidance surrounding model-informed approaches continue to evolve, biosimulation technologies may become more deeply integrated into drug development and regulatory strategies.
Greater regulatory acceptance can encourage pharmaceutical companies to incorporate modeling and simulation earlier and more extensively across development programs.
Competitive Landscape
The biosimulation market includes established technology providers and specialized companies offering software, platforms, services, and modeling expertise.
Key companies operating in the biosimulation market include:
- Certara (US)
- Dassault Systèmes (France)
- Schrödinger, Inc. (US)
- Simulations Plus (US)
- Advanced Chemistry Development, Inc. (Revvity) (Canada)
- Chemical Computing Group ULC (Canada)
These companies are focusing on expanding their biosimulation capabilities, developing advanced modeling platforms, incorporating AI and machine learning, strengthening service offerings, and addressing the evolving needs of pharmaceutical and biotechnology customers.
Future Outlook for the Biosimulation Market
The future of the biosimulation market is closely linked to the continued digital transformation of drug development. As pharmaceutical and biotechnology companies seek ways to reduce development timelines, control costs, improve clinical trial outcomes, and make data-driven decisions, computational modeling is expected to become increasingly important.
The convergence of biosimulation, AI, machine learning, advanced analytics, precision medicine, biologics, and real-world data could further expand the role of modeling and simulation across the pharmaceutical R&D lifecycle.
With the market expected to reach USD 9.24 billion by 2031, biosimulation is positioned to become an increasingly important component of modern drug discovery and development strategies.
Inquire Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=838
Conclusion
The global biosimulation market is expected to witness robust expansion, rising from USD 4.27 billion in 2026 to USD 9.24 billion by 2031 at a CAGR of 16.7%. Increasing drug development complexity, growing adoption of MIDD, AI integration, demand for specialized services, and the expansion of personalized medicine and advanced therapies are creating substantial opportunities for market participants.
While North America currently holds a leading position, Asia Pacific is expected to deliver the fastest growth, supported by expanding pharmaceutical R&D capabilities and increasing investment in computational drug development. As modeling and simulation become more deeply integrated into drug discovery, clinical development, and regulatory decision-making, biosimulation is likely to remain a critical technology for improving the efficiency and predictability of pharmaceutical R&D.